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Disease overview: Approximately one-fourth of cutaneous lymphomas are B-cell derived and
are generally classified into three distinct subgroups: primary cutaneous follicle center lym-
phoma (PCFCL), primary cutaneous marginal zone lymphoma (PCMZL), and primary cutaneous
diffuse large B-cell lymphoma, leg type (PCDLBCL, LT).
Diagnosis: Diagnosis and disease classification are based on histologic review and immunohisto-
chemical staining of an appropriate skin biopsy. Pathologic review and an appropriate staging
evaluation are necessary to distinguish primary cutaneous B-cell lymphomas from systemic B-
cell lymphomas with secondary skin involvement.
Risk stratification: Disease histology remains the most important prognostic determinant. Both
PCFCL and PCMZL are indolent lymphomas that infrequently disseminate to extracutaneous
sites and are associated with 5-year survival rates that exceed 95%. In contrast, PCDLBCL, LT is
an aggressive lymphoma with an inferior prognosis.
Risk-adapted therapy: PCFCL and PCMZL patients with solitary or relatively few skin lesions
may be affectively managed with local radiation therapy. While single-agent rituximab may be
employed for patients with more widespread skin involvement, multiagent chemotherapy is
rarely appropriate. In contrast, management of patients with PCDLBCL, LT is comparable to the
management of patients with systemic DLBCL.
1 | DISEASE OVERVIEW
Primary cutaneous lymphomas are a heterogeneous group of extrano-
dal non-Hodgkin lymphomas, approximately 25% of which are B-cell
derived and are classified into three major entities in the 2008 World
Health Organization-European Organization for Research and Treat-
ment of Cancer (EORTC) joint classification: primary cutaneous follicle
center lymphoma (PCFCL), primary cutaneous diffuse large B-cell lym-
phoma, leg type (PCDLBCL, LT), and primary cutaneous marginal zone
lymphoma (PCMZL).1 The incidence of cutaneous B-cell lymphomas
(CBCLs) has been increasing and is currently ≈4 per million persons,
based on Surveillance, Epidemiology, and End Results registry data,
with the highest incidence rates being reported among males, non-
Hispanic whites, and adults over the age of 50 years.2,3
2 | DIAGNOSIS
Diagnosis and classification of a CBCL requires an excisional or punch
biopsy for careful morphologic and immunohistochemical analysis,
and an appropriate staging evaluation to exclude systemic disease.4
The use of appropriate immunohistochemical stains (eg, CD5, cyclin
D1) may also aid in distinguishing CBCL from secondary skin involve-
ment by a systemic lymphoma.
2.1 | Primary cutaneous follicle center lymphoma
PCFCLs are commonly solitary plaques or tumors involving the
trunk, particularly the head or scalp. While grouped lesions may be
observed, multifocal disease is less common. Histologically, PCFCLs
are characterized by a follicular, diffuse, or mixed growth pattern
comprised of large centrocytes derived from germinal-center B
cells.1,5,6 In contrast to systemic follicular lymphomas, the majority
of PCFCLs do not harbor the t(14;18) translocation involving the bcl-
2 locus, and do not strongly express bcl-2 by immunohistochemistry,
although weak expression may be observed in a minority of cases.7–9
These CBCLs express bcl-6, variably express CD10, and are MUM-
1/IRF-4 negative, consistent with their origin from germinal-center B
cells.
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2.2 | Primary cutaneous diffuse large B-cell
lymphoma, leg type
In contrast to PCFCL, which is an indolent CBCL largely involving the
head and trunk commonly affecting middle-aged adults, PCDLBCL, LT
commonly affects elderly females and presents with rapidly progres-
sive tumors involving the lower legs.10,11 Approximately 10% of cases
may involve other cutaneous sites apart from the lower legs, and
extracutaneous dissemination is common.11 These lymphomas are
characterized by diffuse sheets of centroblasts and immunoblasts that
spare the epidermis, but frequently extend deep into the dermis and
subcutaneous tissue. In contrast to PCFCL, lymphoma cells highly
express bcl-2, likely due to gene amplification,12,13 as t(14;18) is not
observed in PCDLBCL, LT. Dual expression of both bcl-2 and c-myc is
common, and is associated with inferior overall survival compared
with the minority of PCDLBCL, LT that do not express c-myc.13 C-
myc translocations (and “double hits”) are rare among PCDLBCL, LT.13
Most cases are MUM-1/IRF-4 and bcl-6 positive, CD10 negative, and
have a gene expression profile resembling activated B cells.6 Perhaps
not surprisingly, the genetic landscape observed in PCDLBCL, LT is
similar to that observed in activated B-cell-type diffuse large B-cell
lymphoma (ABC-DLBCL), with NF-κB-activating mutations being
observed in CD79B, CARD11, and MYD88.14–17 Of these, somatic
MYD88 L265P mutations appear most common with a prevalence
rate of ≈75%.13,15–17 Despite the use of somatically hypermutated
immunoglobulin heavy-chain variable (IGHV) regions, Staphylococcal
superantigen binding sites within the IGHV are preserved, thus impli-
cating superantigen-dependent B-cell receptor signaling in disease
pathogenesis.18
2.3 | Primary cutaneous marginal zone lymphoma
Patients with PCMZL frequently present with multifocal patches, pla-
ques or nodules involving the trunk and arms. While an association
with Borrelia burgdorferi has been observed in Europe, a similar associ-
ation has not been observed in cases from the United States.19–22
PCMZLs are composed of a mixed infiltrate of small, marginal zone B
cells, lymphoplasmacytic cells, plasma cells, and reactive T cells. Mar-
ginal zone B cells characteristically express bcl-2, but lack bcl-6 or
CD10 expression.
3 | RISK STRATIFICATION
The International Society for Cutaneous Lymphomas (ISCL) and
EORTC recently proposed staging recommendations for cutaneous
lymphomas other than mycosis fungoides and Sezary syndrome.4
Staging should include a history, physical examination, appropriate
laboratory studies (including lactate dehydrogenase), and imaging
(either CT, PET, or increasingly PET/CT) of the chest, abdomen, pelvis,
and neck (in cases with involvement of the head or neck). A bone mar-
row biopsy and aspirate should be performed in cases of PCDLBCL,
LT. The joint ISCL/EORTC does not endorse routine bone marrow
examination in cases of PCFCL or PCMZL, although approximately
10% of patients with PCFCL have bone marrow involvement.23 Bone
marrow involvement was associated with significantly inferior
disease-specific survival. While the TNM staging classification
describes the extent of disease, staging in CBCL is of limited prognos-
tic value, as the disease histology is the major determinant in risk
stratification. This is highlighted by a population-based study which
identified histology and the site of skin involvement as important
prognostic factors.24 In contrast, the International Extranodal Lym-
phoma Study Group identified three independent prognostic factors
(ie, elevated LDH, >2 skin lesions, and nodular lesions) among patients
with PCFCL and PCMZL. These factors were combined to form the
cutaneous lymphoma international prognostic index (CLIPI). The
absence of any adverse prognostic factor was associated with a
5-year progression-free survival of 91%. In contrast, the presence of
two or three adverse prognostic factors was associated with a 5-year
progression-free survival of 48%. As the vast majority of relapses
were confined to the skin, the CLIPI was unable to risk-stratify
patients by overall survival. The presence of multiple skin lesions was
associated with inferior disease-free survival in a European series,25
but was not associated with disease-free survival in a large North
American series.26 The most important factor for risk stratification
among the CBCLs remains the histologic classification. Indolent CBCL
(PCFCL and PCMZL) are associated with 5-year disease-specific sur-
vival ≥95%.1,26 Differences in growth pattern, the density of centro-
blasts, and cytogenetic findings do not appear to provide meaningful
prognostic information. Bcl-2 expression among PCFCL with a diffuse
large B-cell histology may be a notable exception.27 In contrast,
PCDLBCL, LT is associated with a 5-year disease-specific survival of
approximately 50%, and dual bcl-2 and c-myc expression is associated
with inferior survival.1,13,15,28 The presence of a somatic MYD88L265P
mutation is also associated with inferior disease-specific and overall
survival.15 In contrast to patients presenting with only a single tumor,
involvement of multiple sites, on one or both legs, is associated with a
significantly inferior disease-specific survival.29
4 | TREATMENT
As no randomized controlled trials are available, treatment recommen-
dations for CBCL are largely based on small retrospective studies and
institutional experience. The EORTC and ISCL have published consen-
sus treatment recommendations that are consistent with NCCN
guidelines.30 In most cases, optimal patient management requires a
multidisciplinary approach, including dermatology, medical oncology,
and radiation oncology.
4.1 | Primary cutaneous follicle center lymphoma
For patients with solitary lesions, low-dose radiation therapy is safe
and highly affective, with a complete remission rate approaching
100%. Radiation does not appear inferior to multiagent chemotherapy
among patients with multiple lesions that can be included in multiple
radiation fields.31 In a large North American series, the rate of local
control for indolent CBCL with radiation alone was 98%.26 In the
same series, a local recurrence requiring radiation therapy was
observed in 25% of patients who had undergone surgical excision
alone. Reserving radiation until disease recurrence did not appear to
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compromise disease-specific or overall survival.26 Therefore, complete
excision alone, deferring radiation until disease recurrence, is also rea-
sonable. Intralesional (eg, corticosteroids or rituximab32) or topical
therapies may also be considered.33,34 While radiation therapy is gen-
erally recommended for patients with a solitary lesion, radiation ther-
apy, or observation (ie, “watch and wait”) are reasonable options for
those patients with multiple lesions. Patients with more extensive skin
involvement are effectively managed with single-agent rituximab.30
Approximately one-third of patients may relapse following either radi-
ation or single-agent rituximab, but relapses are usually confined to
the skin and are approached in a manner similar to that described for
the initial management of PCFCL.
4.2 | Primary cutaneous marginal zone lymphoma
Patients with PCMZL are approached in a manner analogous to that
described in the initial management of PCFCL. Radiation therapy is
associated with a similarly high response rate for patients with a single
or few lesions.30 Those with more widespread skin involvement may be
observed. Once symptomatic, culprit lesion may be irradiated
(or surgically excised). As for PCFCL, single-agent rituximab may be uti-
lized in patients with symptomatic, widespread skin lesions. An initial
trial of antibiotics for those with B. burgdorferi-associated PCMZL has
been recommended,35 but is less relevant for North American patients.
4.3 | Primary cutaneous diffuse large B-cell
lymphoma, leg type
As previously noted, the natural history of PCDLBCL, LT more closely
resembles that of systemic DLBCL. Therefore, R-CHOP (with or with-
out radiation therapy) is utilized in these patients. While few reports
are available in the literature, the use of R-CHOP in these patients is
associated with disease-free survival rates rivaling those reported for
patients with high-risk systemic DLBCL.10,11,26,30 Most patients pre-
sent with disease confined to the leg(s) and are managed like patients
with limited stage systemic DLBCL with R-CHOP and involved field
radiation therapy. The management of relapsed disease is comparable
to that for relapsed systemic ABC-DLBCL (eg, lenalidomide36 and
ibrutinib37). In a small phase II study (n = 19), the 6-month overall
response rate with single-agent lenalidomide in relapsed/refractory
PCDLBCL, LT was 26%, but was significantly higher in patients with-
out the MYD88L265P mutation.38
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